Ademi LLP is investigating whether the proposed acquisition of Aytu (NASDAQ: AYTU) by Rosemont Pharmaceuticals, provides fair value to Aytu’s public shareholders and whether Aytu’s Board adequately protected shareholder interests in negotiating and approving the transaction.
What Is Ademi LLP Investigating?
- The purchase price and whether it adequately reflects Aytu’s value and future prospects;
- Substantial change-of-control benefits available to Aytu insiders in connection with the transaction;
- Restrictions on competing transactions, including a significant termination penalty that may discourage another potential buyer from making a superior proposal; and
- The conduct of Aytu’s Board of Directors in negotiating and approving the transaction and whether the Board fulfilled its duties to public shareholders.
Join this Action